Acorda to Discontinue Development of Plumiaz for Treatment of Epilepsy Seizure Clusters

ARDSLEY, N.Y., May 20, 2016 --(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of Plumiaz (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news